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A faulty interaction between SOD1 
and hCCS in neurodegenerative 
disease
Gareth S. A. Wright, Svetlana V. Antonyuk & S. Samar Hasnain
A proportion of Amyotrophic lateral sclerosis (ALS) cases result from impaired mutant superoxide 
dismutase-1 (SOD1) maturation. The copper chaperone for SOD1 (hCCS) forms a transient complex 
with SOD1 and catalyses the final stages of its maturation. We find that a neurodegenerative disease-
associated hCCS mutation abrogates the interaction with SOD1 by inhibiting hCCS zinc binding. 
Analogously, SOD1 zinc loss has a detrimental effect on the formation, structure and disassociation 
of the hCCS-SOD1 heterodimer. This suggests that hCCS functionality is impaired by ALS mutations 
that reduce SOD1 zinc affinity. Furthermore, stabilization of wild-type SOD1 by chemical modification 
including cisplatination, inhibits complex formation. We hypothesize that drug molecules designed to 
stabilize ALS SOD1 mutants that also target the wild-type form will lead to characteristics common in 
SOD1 knock-outs. Our work demonstrates the applicability of chromatographic SAXS when studying 
biomolecules predisposed to aggregation or dissociation; attributes frequently reported for complexes 
involved in neurodegenerative disease.
Mutation of superoxide dismutase-1 (SOD1) causes amyotrophic lateral sclerosis (ALS)1. SOD1-related ALS is a 
classical motor neuron disease; pathology is restricted to death of upper and lower motor neurons with cognitive 
impairment reported rarely. Denervation of the neuromuscular junction and motor neuron loss leads to progres-
sive muscle weakness, paralysis and ultimately death, most frequently through respiratory failure. The molecular 
characteristics of this proteopathy proceed from mutant SOD1 structural instability to unfolding and aggrega-
tion2,3. This pathological chain of events begins in the non-symptomatic phase of the disease4,5.
The nascent SOD1 polypeptide must be extensively post-translationally modified. Sequential zinc binding, 
dimerization, copper acquisition and formation of a disulphide bond contribute to SOD1 activation and thermal 
stability6. Zinc binding and disulphide tethering of loop IV increases the thermal stability of wild-type SOD1 
dramatically, shifting its unfolding transition from body temperature for some ALS mutants to 75 °C for the fully 
mature wild-type enzyme7. High stability ensures high concentrations of soluble protein can be maintained. As a 
result, superoxide anions are more likely to encounter SOD1 and begin the detoxification process by conversion 
to hydrogen peroxide. Hindering the SOD1 maturation pathway would however provide much material with a 
propensity for toxic unfolding. This is observed as characteristic SOD1 aggregates in the neural tissue of ALS 
sufferers8–10. Work with transgenic model organisms indicates these inclusions are composed of metal depleted, 
disulphide reduced SOD111–13. A faulty maturation pathway seems to be the cause of SOD1-ALS.
The central facilitator of SOD1 maturation is the multi-domain copper chaperone for SOD1, hCCS, a pre-
dominantly homodimeric enzyme whose central domain bears a high degree of sequence identity with SOD114. 
Both localize in the cytosol and the mitochondrial intermembrane space (IMS). SOD1 disulphide oxidation and 
copper transfer are catalysed by hCCS in the cytosol and during SOD1 import into the IMS15–17. Mitochondrial 
accumulation of mutant SOD1 has been suggested to be an important cause of motor neuron pathology and 
death18. hCCS structural modularity means its functions are not linked19 but the efficiency of disulphide and cop-
per transfer are dependent on the formation of an heterodimeric complex with SOD1 through its zinc-binding, 
SOD1-like domain (D2)20. The relative concentration of hCCS is low with respect to SOD121. Thus one molecule 
of hCCS is believed to interact with several SOD1 molecules through a series of heterodimer complex formation 
and dissociation events perhaps at the membrane-solvent interface22. Mutation of hCCS has been predicted to 
cause its aggregation23 and hCCS can be found with SOD1 in cytoplasmic inclusions8,10. However there were no 
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accounts of human, disease-causing mutations until the discovery of an R163W missense substitution in an indi-
vidual with system-wide and fatal neurological abnormalities in 201224.
Here we describe how pathogenic SOD1 and hCCS mutations that inhibit zinc binding render normal com-
plex formation and disassociation ineffective. hCCS knock-out SOD1 mutant transgenic mice show symptoms 
indistinguishable from their hCCS expressing litter mates25. Our work indicates this is because mutant SOD1 
inhibits hCCS function. This forces a reappraisal of the role of hCCS in SOD1 ALS. We have reconstructed the 
structure of the hCCS-SOD1 heterodimer using small angle X-ray scattering data taken from heterogenous solu-
tions of hCCS, SOD1 and hCCS-SOD1 collected after separation by analytical size exclusion chromatography. 
We found that structural changes to SOD1 present in the metal deficient SOD1 homodimer are also present when 
complexed with hCCS. In addition, we observed that heterodimer complexation is inhibited by chemical modi-
fication of SOD1 with drug-like molecules known to stabilize SOD1 by targeting Cys111 including cisplatin26,27. 
These findings fit an important piece in the puzzle of broken SOD1 maturation in ALS and pose a salutary caution 
to drug discovery efforts that aim to stabilize SOD1 for therapeutic benefit. It is important to ensure that stabili-
zation does not alter complex formation with hCCS and its subsequent disassociation.
Results
R163W hCCS recapitulates the characteristics of ALS mutant SOD1. Initial SAXS analysis indi-
cated wild-type and R163W hCCS have very different structures. R163W however has similar overall scattering 
pattern and size parameters when compared with metal apo-hCCS (Fig. 1a,b). Arg163 is found beside zinc co-or-
dinating His164 in the upper zinc loop. We postulated the substitution would be detrimental to zinc binding and 
confirmed this by ICP-MS analysis; wild-type hCCS was found to contain stoichiometric amounts of zinc (1.0 
zinc ions/monomer) where-as R163W hCCS contained 1.0 zinc ion/13.1 monomers. Wild-type hCCS forms a 
stable dimer when zinc metalated14 but zinc removal shifts the equilibrium in favour of monomer28. Analysis 
of R163W hCCS by size exclusion chromatography shows the protein is predominantly monomeric (Fig. 1c). 
R163W hCCS is however able to form a majority dimer at high concentrations (Fig. 1d). This is reversible upon 
dilution indicative of a shift in the monomer-dimer equilibrium towards the monomer (Fig. 1d).
Incomplete SOD1 metalation impedes acquisition of structural stability. Unfolding and exposure of hydro-
phobic centres ensues29 with spontaneous formation of high molecular mass oligomers at physiological tem-
perature30. Analogously, R163W hCCS is more prone to aggregation than wild-type hCCS under physiological 
Figure 1. R163W hCCS is monomeric and unable to form a heterodimer with SOD1. (a) SAXS from 
R163W hCCS in comparison with Zn-wild-type and metal free hCCS. R163W hCCS radius of gyration is 24.9 Å 
(0.66 < qRg < 1.27) and Dmax 85 ± 5 Å in comparison with 31.3 Å and 118 ± 5 Å for Zn-wild-type10 and 26.4 Å 
and 87 ± 5 Å metal apo-wild-type. (b) Distance distribution function of R163W hCCS and metal apo wild-type 
hCCS. χ 2 R163W 0.88, apo wild-type 0.93. Zn wild-type 0.94. Data used q < 0.4 Å−1. Curves normalized by 
area. (c) SEC showing predominantly monomeric R163W hCCS in comparison with dimeric wild-type. The 
molecular masses of R163W species were calculated by multi-angle laser light scattering to be 29.1 kDa ± 4% 
for the species at 3.19 ml (monomer) and 55.6 kDa ± 10% for the species at 2.98 ml (dimer). SEC performed on 
an Agilent BioSEC-3 column. n = 3. (d) SEC showing concentration dependent dimerization of R163W hCCS. 
Monomeric R163W (15.3 ml) shifts to dimer (14.6 ml) with increasing concentration (blue to red) and moves 
back to monomer after dilution to initial concentration (green). SEC performed on a GE Superdex 200 10/300 
column. Concentrations (μM) are shown in the legend and refer to the protein concentration before application 
to the SEC column.
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conditions (Fig. 2a). In our assay, wild-type hCCS retained more than half of the dimeric starting material with 
reduced appearance of large aggregates in comparison with R163W hCCS. In addition, R163W hCCS is also 
unable to form tetramers (Fig. 2a, 2.75 ml). Aggregation propensity and structural instability are linked by ther-
mal instability. The mid-points of thermally induced unfolding transitions for Zn-wild-type, apo-wild-type and 
R163W hCCS were found to be 56.0 ± 0.5, 49.0 ± 0.8 and 46.6 ± 0.5 °C respectively (Fig. 2b). Therefore, R163W 
hCCS thermal instability exceeds that of zinc demetalated wild-type hCCS.
SOD1 copper acquisition and disulphide reduction by hCCS are dependent on formation of an heterodimeric 
complex mediated by the hCCS central domain20. This heterodimer is of intermediate molecular mass31. Ablation 
of domain two (D2) zinc binding prevents complexation with SOD128,32. Similarly, when R163W hCCS is pre-
sented with reduced SOD1 there is no discernible complex formation (Fig. 2c). This provides a clear explanation 
for the lack of SOD1 activity observed in R163W hCCS homozygous fibroblasts24.
hCCS-SOD1 heterodimer structure and the effect of SOD1 zinc loss. For hCCS to function cor-
rectly the hCCS-SOD1 heterodimer must be a transitory complex. In vitro however the complex can be perpet-
uated by inhibiting SOD1 disulphide formation31. This allows time to study its structure. Zinc metalated ALS 
mutant and wild-type SOD1 form indistinguishable heterodimers with hCCS when observed by small-angle 
X-ray scattering (Fig. 3a). hCCS-SOD1 forms a more compact structure in comparison with the hCCS homod-
imer as evident in the SAXS data (Fig. 3b). Furthermore, the stability deficit conferred by ALS mutations is 
removed when SOD1 is complexed with hCCS (Supplementary Fig. 1). Modelling the heterodimer against the 
SAXS data in Fig. 3a shows the copper binding Atx1 domain closely associated with SOD1 and movement of the 
upper zinc loop without the disulphide bond constraint (Fig. 3c).
Zinc metalation is thought to be the first step in the succession of SOD1 post-translational modification 
(PTM) events16 however weakened affinity for zinc is a common trait of ALS SOD1 mutants33–38. Apo-SOD1 is 
able to form an heterodimeric complex with Zn-hCCS20. When apo-SOD1 complexes with hCCS several impor-
tant differences are observed: Complex formation does not go to completion; hCCS and apo-SOD1 homodimers 
remain in the solution (Fig. 4a,b) and the hydrodynamic radius (Rh) of the complex increases as evidenced by a 
shift in its elution position from SEC. The SAXS profile changes and the radius of gyration (Rg) increases from 
24.8 to 26.2 Å (Fig. 4c,d). Heterodimer complex disassociation is inhibited regardless of the copper loading of 
hCCS or ALS mutations of SOD1 (Fig. 5). This clearly demonstrates that SOD1 zinc loss induces structural and 
Figure 2. R163W hCCS recapitulates the molecular characteristics of ALS mutant SOD1 and cannot 
form a complex with SOD1. (a) Upper - SEC showing zinc metalated wild-type hCCS aggregation. 34% wild-
type dimer (2.9–3.15 ml) is lost to aggregation (1.7–2.9 ml) after 48 hours in comparison with Lower - 63% of 
R163W monomer (3.1–3.35 ml). After 24 hours 10 and 16% of wild-type dimer and R163W monomer are lost 
to aggregation respectively (data not shown). Increased static light scattering at 90o (red chromatograms) over 
elution volume around 2.3 ml indicates the presence of more high molecular mass species for R163W. n  =  3.  
(b) DSF showing that R163W hCCS is thermally unstable. At 26 °C Zn-wild-type hCCS, apo-wt hCCS and 
R163W hCCS exhibit equal reporter fluorescence indicating all three proteins share comparable hydrophobic 
residue exposure. R163W and apo-wt hCCS begin to unfold as soon as the temperature starts to rise. This 
contrasts Zn-wild-type hCCS, which shows no increase in fluorescence until approximately 45 °C signifying 
resistance to thermal unfolding. n = 8 with standard deviation for 1 in 3 data points and mid-point melting 
temperature plotted. (c) SEC indicating that R163W hCCS cannot heterodimerize with SOD1. A 1:1 
stoichiometric mixture of R163W hCCS and SOD1 does not shift the component proteins from their respective 
monomeric (3.19 ml) and homodimeric (3.33 ml) positions. n = 3.
www.nature.com/scientificreports/
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functional abnormalities in the heterodimer formed with hCCS. These changes are comparable with those found 
in the immature, zinc deficient SOD1 homodimer (Supplementary Figs 2 and 3) and are indicative of a loosening 
of the compact protein structure39.
Stabilizing chemical modifications inhibit heterodimer formation. Stabilizing SOD1 by binding 
small molecules to specific sites that mediate SOD1 toxicity has shown promise as a strategy to develop targeted 
therapeutics26,27,40. Crosslinking opposing SOD1 monomers offers the potential to permanently inhibit dimer 
disassociation and greatly increases the protein’s thermal stability26. However, complex formation with hCCS 
necessitates SOD1 homodimer disassociation and covalent dimer tethering with Bismaleimidoethane (BMOE) 
completely inhibits heterodimer formation (Fig. 6a). Covalent addition of cisplatin does not crosslink opposing 
monomers but has been shown to increase SOD1 stability and strongly disfavour aggregation27. In this case het-
erodimer formation is inhibited but not completely (Fig. 6b) and may reflect the 50% occupancy of cisplatin in a 
SOD1 dimer27.
Discussion
Proteins interact with their surroundings throughout their lifetime. This decides their location, function, the 
timing and means of their degradation or any pathogenic effects. The efficacy of these interactions is therefore 
very important. Retrieving structural information from these biomacromolecular conjugates is however often 
complicated by their presence in heterogeneous states; conformational plasticity, oligomeric equilibria, aggrega-
tion and degradation for example. The case in point, the hCCS-SOD1 complex, has been intensely studied since 
the discovery of CCS but has been refractory to structural characterization due to its size, transient nature and the 
difficulty of isolating it in pure form. Small angle X-ray scattering coupled with a size exclusion chromatography 
stage allows one to pick small tranches of data from otherwise polydisperse solutions14. Here we have been able 
to create a model of the complete, wild-type human CCS-SOD1 heterodimer using data taken from a solution 
otherwise contaminated by uncomplexed constituents.
Figure 3. ALS-SOD1 mutants form a compact heterodimer with hCCS. (a) Small angle X-ray scattering by 
ZnSOD1-ZnCCS. Wild-type, H46R and I113T–hCCS heterodimer complexes have superimposable scattering 
patterns and indistinguishable size parameters; Rg 24.8 ± 0.3 Å, Dmax 78 ± 6 Å, n = 8. Mutant and wild-type 
SOD1-hCCS complexes co-elute from SEC indicating identical hydrodynamic radii (data not shown).  
(b) The hCCS-SOD1 heterodimer has a conformationally rigid, globular structure. Dimensionless Kratky plot 
of X-ray scattering from hCCS, SOD1 and the hCCS-SOD1 heterodimer indicates the conformational flexibility 
displayed by the hCCS homodimer is lost when complexed with SOD1. A folded protein will have a peak 
maximum at √ 3 and 1.1. Increased conformational flexibility pushes the peak further into the positive section 
of the graph, quadrant I, as can be seen for homodimeric hCCS. In contrast, ZnSOD1-hCCS does not show any 
more conformational plasticity than the Zn-SOD1 homodimer. (c) Centre – Structure of Zn-wtSOD1-hCCS 
heterodimer modelled against experimental SAXS data. Right – Agreement of SAXS data (blue) with computed 
model scattering pattern (red), χ 2 1.5 and volatility ratio (VR)68 0.37 over 0.0242 < q < 0.5 Å−1. Fitting residuals 
are shown in Supplementary Figure S4. Left – The SOD1 zinc loop in situ at the SOD1-hCCS dimer interface. 
Blue shows the position of the disulphide bonded loop as found in the SOD1 homodimer and magenta shows 
the loop’s position in our model in the disulphide reduced state indicating conformational mobility and changes 
to the dimer interface.
www.nature.com/scientificreports/
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Understanding of SOD1-related ALS has grown with observations of the mutant protein in silico, in vitro, cell 
and animal models, and histopathology of post-mortem CNS tissue. The coherent theme across SOD1 studies is 
that structural instability resulting from disease-causing mutations promotes unfolding and monomerization. A 
symptom of this process is aggregation of SOD1 within effected motor neurons and associated tissues41, denerva-
tion at neuromuscular junctions and nerve death. Conversely, wild-type SOD1 is a perfect example of evolution-
ary bioengineering; small, compact, structurally solid and highly active. Zinc binding and disulphide bonding 
synergize to lock the protein’s conformation. SOD1 loop IV houses all the zinc co-ordinating amino acid side 
chains, a cysteine involved in disulphide bonding and forms part of the SOD1 dimer interface. This long loop 
shows a high degree of conformational freedom that reduces homodimer affinity when zinc and the disulphide 
are absent42. Zinc bound, disulphide reduced SOD1 is the normal substrate for hCCS. In this state half of loop 
IV is tethered and conformational flexibility around Cys57 is limited. This form must have a higher affinity for 
hCCS than itself. Disulphide transfer anchors loop IV and forms the stable dimer interface. This shifts the affinity 
Figure 4. Heterodimer formation and structure is disturbed by SOD1 zinc loss. (a) Upper - Size exclusion 
chromatogram of zinc wild-type SOD1-hCCS heterodimer (3.16 ml) formation under reducing conditions. 
The reaction goes to completion with little homodimeric SOD1 or hCCS remaining. n = 3. Lower - The 
complexation reaction between zinc deficient wild-type SOD1 and hCCS does not go to completion. 
Homodimeric hCCS and apo-SOD1 remain in solution (3.02 and 3.42 ml respectively). Elution of the hCCS-
SOD1 complex is also shifted to 3.14 ml indicating increased hydrodynamic radius. n = 3. (b) Upper -  
SEC time course of zinc A4V SOD1-hCCS heterodimer complex formation separated by SEC under non-
reducing conditions (blue to red chromatograms show 8 minutes to 4 hours after complexation). The A4V 
SOD1 heterodimer forms then disappears as the SOD1 cysteine thiols are oxidized to form the disulphide 
and homodimeric SOD1 is evolved. In comparison with, Lower - evolution and subsequent disassociation of 
apo-A4V SOD1-hCCS. A small amount of heterodimer is observed between elution of homodimeric hCCS 
and SOD1 at 3.16 ml and much less SOD1 homodimer is evolved. (c) SAXS curves for zinc and apo wild-type 
SOD1-hCCS heterodimer. (d) P(r) function of c showing significant real-space conformational differences. 
Data used: 0.022 < q < 0.4 Å−1, Dmax ZnSOD1-hCCS 90 Å, apoSOD1-hCCS 89 Å. ApoSOD1-hCCS χ 2 0.91, 
ZnSOD1-hCCS χ 2 1.01. Curves normalized by area.
Figure 5. Heterodimer disassociation is inhibited by SOD1 zinc loss. (a) SEC showing dissociation of copper 
apo/zinc holo hCCS-SOD1 heterodimer after 20 hours of incubation following initial complexation. Red – metal 
apo SOD1-hCCS, Blue – Zinc metalated SOD1-hCCS. Less heterodimer and more SOD1 homodimer can 
be observed when zinc metalated SOD1 dissociates from hCCS. (b) As above, but hCCS domain I is copper 
metalated. (c) As above with A4V mutant SOD1. The amount of apoA4V SOD1-hCCS heterodimer remaining 
is more than for the zinc metalated form and the amount of dimeric SOD1 evolved is less.
www.nature.com/scientificreports/
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of SOD1 from hCCS to favour homodimerization. In this final act copper can be donated to SOD1 creating the 
active and stable enzyme capable of performing its biological function of dismutation of superoxide.
Here we have shown reduced metalation resulting from the R163W neurodegenerative disease-associated 
mutation in hCCS; a situation analogous to the diminished zinc affinity of ALS-SOD1 mutants. The R163W sub-
stitution prevents hCCS forming the critical heterodimer with SOD1 (Fig. 2c), greatly reduces SOD1 activity and 
triggers unfolded protein response markers24. Several other lines of evidence also indicate that the hCCS-SOD1 
interaction is effected by disease causing mutations: 1) hCCS overexpression in a G93A SOD1 mouse causes 
extreme ALS-like symptoms and drastically reduces life-expectancy43, 2) hCCS over-expression increases the 
proportion of disulphide oxidized wild-type SOD1 but not ALS mutant SOD144, 3) SOD1 is found to be metal 
depleted and disulphide reduced in the inclusions found in mutant SOD1 transgenic animal models11–13. 4) SOD1 
activity is lower in tissues from SOD1-ALS sufferers3,45. Activity may be reduced by proteolysis, aggregation or 
inability to copper metalate, indeed SOD1 copper loss leads to aggregation which correlates with disease sever-
ity46, but each characteristic is indicative of heterodimer malfunction given hCCS’s dual function.
Our observations of the complex formed between SOD1 and wild-type hCCS confirm the notion of a faulty 
interaction in ALS. Each step in the homodimer-heterodimer-homodimer cycle requires changes to the SOD1 
dimer interface and the efficacy of each step is determined by SOD1 zinc metalation. Heterodimer formation 
between hCCS and zinc-SOD1 is fast and complete under reducing conditions but complexation is inhibited by 
SOD1 zinc loss (Fig. 4a,b). For wild-type homozygous individuals this delicate balance of affinities prioritises zinc 
loaded SOD1 for interaction with hCCS. This distinction must be made because copper acquisition in the absence 
of zinc yields a catalytically inactive enzyme47. However, ALS SOD1 mutations reduce the affinity for zinc33–38. 
The high cellular chelation capacity will divert zinc to other destinations leaving mutant SOD1 zinc free and with 
reduced potential for hCCS catalysed disulphide formation.
The portion of metal deficient SOD1 that does complex with hCCS has a structural perturbation that inhib-
its its dissociation (Fig. 4a,c,d). We propose that increased loop IV mobility in the absence of SOD1 zinc slows 
catalysis of disulphide transfer by hCCS and increases the life-time of the heterodimer complex. Also, copper 
transfer to SOD1 cannot take place under these circumstances20. hCCS recycling would be prevented when metal 
deficient SOD1 is unable to relinquish its chaperone. Nascent SOD1, whether wild-type or mutant, then has a 
reduced chance of forming a complex with hCCS. The susceptibility of mutant SOD1 to disulphide reduction will 
exacerbate this effect48,49 as will increasing the amount of mutant SOD1, as in the case of transgenic mouse mod-
els25. These situations effectively create an hCCS functional knock-out by further depleting the pool of available 
hCCS; a scenario that provides material for accumulation of small toxic oligomers50,51, aggregate growth13 and 
cell to cell propagation52 by hindering SOD1 maturation. It is also interesting to note that heterodimer formation 
with hCCS alleviates the destabilizing effect of ALS mutations (Supplementary Fig. 1). Increasing the amount of 
Figure 6. hCCS-SOD1 complex formation is inhibited by exogenous covalent stabilization of the SOD1 
dimer. (a) Covalent tethering of SOD1 monomers by addition of BMOE to opposing Cys111 residues 
completely inhibits heterodimerization with hCCS as observed by SEC. n = 3. (b) Upper - Addition of cisplatin 
to SOD1 Cys111 inhibits heterodimer formation with hCCS. The curves shown are representative of three 
chromatograms. Lower-SDS-PAGE of 0.5 ml fractions taken from the SEC above showing reduced SOD1-hCCS 
complex formation after SOD1 Cisplatin binding. It is also clear from the SOD1 and SOD1-CisP SDS-PAGE 
that cisplatin does not cause covalent tethering of the SOD1 dimer.
www.nature.com/scientificreports/
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hCCS and mutant SOD1 creates an abundance of long-lived, thermally stable complexes. This may explain the 
lack of SOD1 misfolding and aggregation observed in SOD1 transgenic mouse and cell models where hCCS is 
overexpressed43,44,53.
Stabilizing the zinc bound, disulphide-reduced form of SOD1 by chemical modification prevents complex-
ation with hCCS (Fig. 6). This would inhibit the chaperone’s functions20. Blocking the route of copper to SOD1 
through hCCS has been shown to inhibit cancer proliferation54. We note that inhibiting the direct interaction of 
SOD1 with its chaperone may indeed be the contributory factor in the success of cisplatin as a cancer therapeutic. 
SOD1 knock-out does not cause ALS but does lead to denervation in a manner similar to the normal aging 
process and a host of other complications. This presents a problem if we are to stabilize SOD1 for therapeutic 
benefit in ALS. Cys111 modification is currently the only valid non-native strategy to stabilize SOD1. What 
remains to be seen is the effect of stabilization at alternative sites. It is clear however that any perturbation of 
the affinities that regulate complex formation and disassociation would negatively affect both SOD1 disulphide 
formation and copper activation. A stabilizing molecule that specifically targeted the mutant protein without 
binding the wild-type form would circumvent this problem. However more tractable options may include preven-
tion of the interactions that lead to aggregation or stimulation of hCCS mediated SOD1 maturation. Diacetyl-bi
s(4-methylthiosemi-carbazonato)copperII uses the latter route along the CtrI-hCCS-SOD1 copper trafficking 
pathway to stabilize intracellular SOD1 and improve transgenic SOD1 mouse survival55–57. This underscores both 
the role of hCCS in ALS but also its potential for therapeutic intervention.
Materials and Methods
Protein production, oligomeric state, aggregation and thermal stability. SOD1 and hCCS recom-
binant proteins were produced as described previously14,40. Metal apo proteins were produced as described58–60 
and metal ion content was determined by ICP-MS where applicable. Protein concentrations were determined by 
absorbance at 280 nm using monomer molar extinction coefficients. R163W concentration dependent dimeri-
zation was observed on a Superdex 200 10 300 column with soluble phase flow 0.5 ml/min in 20 mM Tris-HCl, 
150 mM NaCl (TBS) with 1 mM DTT. 500 μ l sample was loaded at concentrations ranging from 26 to 918 μ M. 
The high concentration protein was then diluted back down to 30 μ M. SOD1-hCCS complex formation was 
achieved by overnight reduction of SOD1 with 40 mM dithiothreitol (DTT) at 4 °C and mixing at a 1:1 molar 
ratio with hCCS before SEC. SEC was then performed at 20 °C on an Agilent 1260 series HPLC using an Agilent 
BioSEC-3 4.6 × 300 mm column with 3 μ m bead size and 300 Å pore size at a soluble phase flow rate of 0.4 ml/min 
in TBS with 1 mM DTT unless otherwise stated. Complex dissociation experiments were performed after SOD1 
reduction and desalting into oxygen purged TBS. hCCS was copper loaded with tetrakis(acetonitrile)copper(I) 
hexafluorophosphate under anaerobic conditions followed by desalting. hCCS loaded with copper (I) had 87% 
occupancy as determined by ICP-MS. Reactions were incubated at 20 °C over a time-course then separated by 
SEC. To find the relative aggregation propensity of R163W hCCS both wild-type and mutant were incubated 
at 37 °C over a 48 hour time-course. Samples were taken at 0, 24 and 48 hours then separated by SEC using UV 
absorption and static light scattering (658 nm) to monitor protein aggregation. Protein thermal stability was 
determined by differential scanning fluorometry. In each case, fluorescence (Ex: ~470 nm , Em: ~610 nm) was 
measured from 10 μ M protein with 40× Sypro-orange dye heated at 1 °C min−1 from 25 to 95 °C. Melting temper-
atures were defined as the temperature at half peak height of the unfolding transition using SimpleDSFviewer59.
Small-angle X-ray scattering and model building. Small angle X-ray scattering measurements were 
performed using the SEC-SAXS apparatus at beamline SWING60, Synchrotron Soleil. Acquisition of SOD1, 
hCCS and hCCS-SOD1 complex data has been described previously14,61. R163W SAXS data were collected after 
separation of 6 nmoles protein on an Agilent BioSEC-3 4.6 × 300 mm column with 3 μ m bead size and 100 Å 
pore size. Distance distribution functions for ZnSOD-hCCS and apoSOD1-CCS were calculated using data 
0.02 < q < 0.4 Å, Dmax 89 and 90 Å, χ 2 1.00 and 0.96 respectively using GNOM62 and ScÅtter. Initial models of 
wild-type zinc loaded hCCS monomer were generated by I-Tasser from the primary sequence including cloning 
fragment63. The initial orientation of the SOD1-hCCS domain II interface was achieved by substituting the crystal 
structure of hCCS D2 (1DO5)64. This was followed by alignment of an human SOD1 monomer (2C9V)65 to the 
opposing hCCS D2 monomer. Five heterodimers were constructed in this fashion using five output models from 
I-Tasser. The model with lowest χ 2 (4.93) against experimental data was used in subsequent steps. Disulphide 
bonds were removed and disulphide loops designated as flexible (SOD1 amino acids 50–62, hCCS 134–146). 
The positions of domains and loops were then modelled by torsion angle molecular dynamics (MD) using CNS 
with the SOD1-hCCS domain II interface locked66. MD simulations were performed at 300,000 K, after energy 
minimization, without simulated annealing. The procedure began with 40–80 ps simulations with infrequent 
sampling. When modelling coalesced around an arrangement of domains, 1–10 ps simulations with frequent 
sampling were used to optimize the structure. At each stage models were compared to experimental data using 
FoXS67.
Complexation with chemically modified SOD1. BMOE and cisplatin were covalently bonded to SOD1 
using the protocols of Auclair et al.26 and Banci et al.27 respectively. SOD1 was reduced and complexed with hCCS 
as above with the exception that 100 nmoles of hCCS and SOD1 with or without cisplatin bound were separated 
by SEC on a Superdex 75 10 300 column and fractions taken for analysis by reducing SDS-PAGE.
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